Stem cell therapy is a kind of procedure used for treating or preventing a disease from spreading further into the body. It is the fastest-growing as well as the largest segment under regenerative medicine. Stem cells have the capability to grow new cells, replicate themselves, or replace damaged cells in the body. Moreover, stem cell therapies are also used for treating various chronic diseases like cancer and other blood disorders, thereby boosting the growth of the market for stem cell therapy.
The Stem Cell Therapy Market is expected to reach USD 161.8 million by 2022, growing at a CAGR of 11.0% during the forecast period. Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global stem cell therapy market.Product Analysis
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48
On the basis of therapeutic application, the global stem cell therapy market is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of 61.1% in the global stem cell therapy market in 2017. Furthermore, the CVS diseases segment is expected to grow at the highest CAGR of 13.0% during the forecast period. This large share can be attributed to the rising availability of stem cell-based products for the treatment of musculoskeletal disorders, high prevalence of musculoskeletal disorders and bone & joint diseases, and growing patient preference for effective & early treatment strategies.
On the basis of cell source, the global stem cell therapy market is divided into adipose derived MSCs; bone marrow derived MSCs, embryonic / cord blood SCs, and other cell sources. The adipose derived MSCs segment was expected to account for the largest share of 59.1% in the global stem cell therapy market in 2017. Furthermore, the bone marrow derived MSCs segment is expected to grow at highest CAGR of 12.1% during the forecast period.
Read more (Stem Cell Therapy Market):-
As of 2016, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global stem cell therapy market.
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly